Related references
Note: Only part of the references are listed.Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro
Anne Christine W. Vos et al.
INFLAMMATORY BOWEL DISEASES (2012)
Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide series
Eric Toussirot et al.
JOINT BONE SPINE (2012)
P011 Anti-TNF-alpha induces a dysregulated tissue-homing profile on human immune cells in-vitro
S. Peake et al.
Journal of Crohns & Colitis (2012)
Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohn's Disease
Sergio Rutella et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Raja Atreya et al.
GASTROENTEROLOGY (2011)
Serial Changes of Cytokines in Crohn's Disease Treated with Infliximab
Tomomi Mizutani et al.
HEPATO-GASTROENTEROLOGY (2011)
Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease
Antonio Di Sabatino et al.
INTERNAL AND EMERGENCY MEDICINE (2011)
Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti-Tumor Necrosis Factor Therapy
Jean-Francois Rahier et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Angiogenesis and vasculogenesis in rheumatoid arthritis
Zoltan Szekanecz et al.
CURRENT OPINION IN RHEUMATOLOGY (2010)
Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: Biological roles and effects of TNF and TNF antagonists
Yehuda Chowers et al.
JOURNAL OF CROHNS & COLITIS (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
The expanding role of biologic therapy for IBD
Stephen B. Hanauer
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments
J. Seneschal et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Predictive Factors of Eczema-Like Eruptions among Patients without Cutaneous Psoriasis Receiving Infliximab: A Cohort Study of 92 Patients
Abdolrasool Esmailzadeh et al.
DERMATOLOGY (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease
S. Brand
GUT (2009)
Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies
Walter Fries et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
J. Schmitt et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells
Clare A. Notley et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents
Andrew Nesbitt et al.
INFLAMMATORY BOWEL DISEASES (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases
Herbert Tilg et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions
Gillian C. de Gannes et al.
ARCHIVES OF DERMATOLOGY (2007)
Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β
Suchita Nadkarni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease
Jan M. H. Van den Brande et al.
GUT (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Mini-review: How T lymphocytes switch between life and death
Ruediger Arnold et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation:: A novel anti-inflammatory mechanism of infliximab in Crohn's disease
S Danese et al.
JOURNAL OF IMMUNOLOGY (2006)
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis
Silvio Danese et al.
GASTROENTEROLOGY (2006)
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
FO Nestle et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Characteristics of intestinal dendritic cells in inflammatory bowel diseases
AL Hart et al.
GASTROENTEROLOGY (2005)
TNF pathophysiology in murine models of chronic inflammation and autoimmunity
G Kollias
SEMINARS IN ARTHRITIS AND RHEUMATISM (2005)
Cross-regulation of TNF and IFN-α in autoimmune diseases
AK Palucka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression
FJ Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept
C Shen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α
H Mitoma et al.
GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor α antibody treatment
S Zeissig et al.
GUT (2004)
Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form
N Corazza et al.
GASTROENTEROLOGY (2004)
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy
MR Ehrenstein et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The CD40/CD40L costimulatory pathway in inflammatory bowel disease
S Danese et al.
GUT (2004)
Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease
M Ringheanu et al.
INFLAMMATORY BOWEL DISEASES (2004)
Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease
A Di Sabatino et al.
GUT (2004)
Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms
M Bruewer et al.
JOURNAL OF IMMUNOLOGY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Binding and functional comparisons of two types of tumor necrosis factor antagonists
B Scallon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
T ten Hove et al.
GUT (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
A Lügering et al.
GASTROENTEROLOGY (2001)
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
N Kadowaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease
J Agnholt et al.
CYTOKINE (2001)
Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4(+) T cells
S Harashima et al.
JOURNAL OF IMMUNOLOGY (2001)
Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages
G Eissner et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
